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Summary Hematological and biochemical parameters were evaluated in 31 patients receiving 150 MBq
89Strontium (89Sr) intravenously due to painful skeletal metastases from hormone resistant prostate cancer.
Two and 3 months after the injection prostate specific antigen (PSA) had increased by a median of 36% and
100%, respectively, as compared to the pretreatment value whereas alkaline phosphatase (APHOS) had
decreased by about 20% (median). The leucocyte and platelet counts were reduced by about 20-35%, without
reaching grade >2 toxicity.
Pain relief was reported in 14 of 29 evaluable patients at 2 months and in 11 of 23 patients at 3 months.
It is concluded that 89Sr represents a worthwhile therapeutic modality in the palliation treatment of patients
with hormone resistant prostate cancer, though the biological significance of frequently increasing PSA and
decreasing APHOS is not yet completely understood.
One principal aim of the treatment of hormone resistant
prostate cancer is the relief of mestastatic bone pain (Tan-
nock et al., 1989; Zelefsky et al., 1989).
Recently 89Strontium (89Sr) has been reported to be highly
effective as palliation treatment in patients with painful bone
metastases from hormone resistant prostate cancer (Robin-
son et al., 1989; Bolger et al., 1991; Lewington et al., 1991).
Though, the hematological changes and the palliation effect
during 89Sr therapy have been discussed extensively, only
limited information is available on changes of the bio-
chemical parameters which mirror the course of the disease,
as prostate specific antigen (PSA) and alkaline phosphatase
(APHOS). In the present report we discuss our results of a
phase II study primarily dealing with the changes of PSA and
APHOS in patients who have received 89Sr due to painful
bone metastases from hormone resistant prostate cancer. In
addition, the palliation effect of the treatment is discussed.
Patients and methods
Follow-up
This was done at 4, 8 and 12 weeks. The following clinical,
hematological and biochemical parameters were assessed
before the 89Sr injection and at each follow-up: Performance
status (WHO, [Miller et al., 1981]), hemoglobin (Hgb), leu-
cocyte counts, thrombocytes, APHOS, PSA. The bone scan
was repeated at 3 months.
Evaluation ofsubjective response
At each attendence the doctor assessed and scored the use of
analgesics by the following scoring system: (analgesic score) 0
- analgesics not required, 1 - non-narcotic analgesics occa-
sionally required, 2 - non-narcotic analgesics regularily
Table I Patient characteristics
No. ofpatients
From December 1990 to February 1992 31 patients with
hormone resistant prostatic cancer and painful metastases
(Table I) were included in a phase II study which evaluated
the palliation effect of 89Sr (Amersham, International plc,
Amersham, Bucks, England). All patients underwent 99mTc
bone scan which was quantitated according to Soloway et al.
(1988) (0: No hot spots; 1: 1-5 hot spots; 2: 6-20 hot spots;
3: >20 hot spots; 4: Superscan = > 75% involvement of
vertebrae, ribs, pelvis). Eligibility criteria were: Performance
status <2 (Miller et al., 1981; > 12 hot-spots on the 99mTc
bone scan; Leucocytes >3.0 x 109 1'; thrombocytes > 120 x
109I-1', serum creatinine <150ymol 1', no urinary incon-
tinence, informed consent.
Treatment
The patients received 150 MBq 89Sr intravenously at the out-
patient clinic. All patients were informed about hygienic
precautions at home during the first week after the injection
in order to avoid uncontrolled spread of the radioactive
substance by urine or blood.
Evaluation and age
Total included
Inevaluable for subjective response
Evaluable 2 monthsa
Evaluable 3 months
Age (years)b
Androgen-deprivation
Orchietomy
LH-RH analogues
Performance status (WHO)
0
1
2
Use ofanalgesics
No analgesics
Non-narcotics irregularly
Non-narcotics regularly
Narcotics irregularly
Narcotics regularly
Bone scan (EOD)'
1
2
3
4
Pre-treatment laboratory tests
Hemoglobin (g dl-')
Leucocytes (09 1 ')
Thrombocytes (I09 1')
Alkaline phosphatase (U I')
PSA (tg 1-')
31
2
29
23
70c (52_79)d
24
7
2
23
6
8
11
1
10
16 16
8
Median (Range)
12.2 (9.1-15.3)
7.3 (4.5-13.4)
304 (161-598)
871 (188-4631)
159 (6-2182)
aIncluding 4 patients with early progression; bAge; cMedian; dRange;
'Extent of the disease.
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required, 3 - oral or parenteral narcotic analgesics occa-
sionally required, 4 - oral or parenteral narcotic analgesics
regularily required. In addition, the patients were asked to
answer the EORTC Quality of Life Questionnaire (Qol)
(Aaronson et al., 1991) before the 89Sr injection and at each
follow-up. At each follow-up visit a mean score was cal-
culated from the answers to the four questions dealing with
pain which were scored by a 4-point Likert scale (1: not at
all; 2: a little; 3: quite a bit; 4: very much). The condition for
improvement ofpain (as assessed by the patient) was that this
mean pain score had decreased with at least 0.5 as compared
to the pre-treatment scoring. Similarly, deterioration ofpain
was defined by increase of the mean score by at least 0.5.
Based on the information on use of analgesics (by the
doctor) and the patient's pain scoring the following response
categories were defined. Response: Reduction of analgesic
score by at least one step or an unchanged analgesic score
but reduction of the daily dose by >25% (doctor's assess-
ment) combined with unchanged/improved pain (question-
naire). Progression: Increase of the analgesic score by at least
one step or increase of the daily analgesic dose by at least
25% or clinical need to give additional non-analgesic anti-
pain treatment (i.e. radiotherapy), and/or deterioration of
pain as expressed by the patient in the questionnaire. No
change: Between response and progression.
Response was evaluated at 2 and 3 months, respectively.
Patients who fullfilled the criteria for progression before 2
months had elapsed were categorised within an 'early pro-
gression' category.
Subjective toxicity
There was no subjective toxicity in any of the cases except
for a 1-2 days' flare reaction in six patients.
Biochemical andhematological changes
The relative changes of hemoglobin and of the leucocytes,
thrombocytes at 1, 2 and 3 months, respectively are given in
Table III and Figure 1, together with the changes of PSA
and APHOS. At 2 months a median increase of PSA of 36%
was observed (Range: 40% reduction to 280% increase). At 3
months PSA had increased with a median of 100% (Range:
43% reduction to 460% increase). The comparable reduction
of APHOS was 20% (Range: 72% reduction to 327% in-
crease) at 2 months and 16% at 3 months. Neither at 2 or 3
months there was any correlation between the subjective
response and changes of PSA or APHOS. The leucocyte and
thrombocyte counts decreased by a median of about
20-35% at 2 and 3 months, without reaching WHO toxicity
grades )2 (Miller et al., 1981) in any case.
Reduced intensity of pre-treatment hot spots could be seen
in three of the 23 patients examined by bone scintigraphy at
3 months (Figure 2a). None of these three patients displayed
raising APHOS levels at any time during their 3 months
follow-up period. In most patients with a 3 months bone
scan the number and/or the intensity of hot spots had in-
creased (Figure 2b), most often combined with reduced
APHOS values.
Statistics
The PC based statistical programme 'Medlog' (Information
Analysis Corporation, Mountain View, CA 94040, USA,
1991) was used for calculation of medians, ranges and the
chi-square test. A P value less than 0.05 was regarded as
statistically significant.
Results
Twenty-nine patients were evaluable for response after 2
months (including four patients with early progression) and
23 patients at 3 months. Two patients were judged to be
inevaluable for response to 89Sr treatment. One had a patho-
logical fracture of the spine 3 weeks after the 89Sr injection,
the other developed very painful herpes zoster capitis 4 weeks
after the 89Sr injection.
Subjective response
Fourteen of the 29 patients responded after 2 months (Table
II). The comparable figure after 3 months was 11 of the 23
patients who remained on study for 12 weeks. After 2
months six patients had progressed including four patients
with early progression. Seven additional patients had pro-
gressed at 3 months.
Objective response
In three patients objective progression of measurable lymph
node or soft tissue metastases (Miller et al., 1981) was
recorded at the 3 months follow-up visit. Two of these three
patients had responded subjectively at the same time.
Table II Pain relief after 89Sr injection
2 months 3 months
No. of evaluable patients 29 23
Response 14 11
No change 9 5
Progressiona 6a 7
aIncluding four patients with early progression.
Discussion
The assessment of pain and of pain relief represents one of
the most difficult tasks in the palliation treatment of patients
with hormone resistant prostatic cancer. In general, doctors
are not sufficiently aware of their patients' pain and analgesic
treatment is not rarely inadequate (Dorrepaal et al., 1989).
The use of analgesics (types, dose) only roughly mirrors the
patients' pain experience. In particular, recording these para-
meters alone does not give sufficient information whether
patient does or does not experience any pain. This might on
one hand be related to the patient's preference: Some patients
prefer a certain level of pain rather than suffering from side
effects from strong, effective analgesic treatment. In other
cases a busy doctor with limited time to spend together with
a patient does not always adequately perceive a patient's pain
level. Therefore, the present assessment of pain reliefis based
on combined assessment as done by the doctor (type and
doses of analgesics) and the patient's description of pain as
scored in the Qol questionnaire.
Table III Changes (% of pre-treatment value) of hematological and
biochemical parameters
Timea
Hemoglobin
Leucocytes
Thrombocytes
Alkaline phosphatase
2
3
2
3
2
3
2
3
% Change'
_2C (l19-+32)d
-3 (-17-+26)
-6 (-33- +23)
-21 (-69- +20)
-36 (-84--8)
-22 (-48- + 104)
-29 (-52- +59)
-25 (-54- +15)
-29 (-59- +3)
-26 (-59- +96)
-23 (-72- +327)
- 19 (-67- +71)
1 +40 (-33- +214)
PSA 2 -36 (-40- +280)
3 - 100 (-43- +460)
aMonths after89Sr injection. bPositive figures (+): Increase; Negative
figures (-): Decrease. cMedian. dRange.TREATMENT OF PROSTATE CANCER WITH 89Sr
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Figure 1 a, Changes of PSA (% of pre-treatment value) 1-3 months after 89Sr injection.' -Median. b, Changes of APHOS (% of
pre-treatment value) 1-3 months after 89Sr injection. Median.
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Figure 2 Changes of the pre- and post-treatment (3 months) 99mTc bone scan in patients receiving 59Sr due to metastatic cancer of
the prostate. Pre-treatment: above; Post-treatment: below, a, Reduced intensity of hot spots. b, Increased number of hot spots.
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Our results on subjective response at 2 and 3 months are in
agreement with published observations (Robinson et al.,
1989; Bolger et al., 1991; Laing et al., 1991). 89Sr treatment
seems thus to be a worthwhile alternative in the palliation
treatment in these patients, in particular as the therapy is
easy to administrate and virtually without subjective toxicity.
However, the duration of response in our patients seems
shorter than reported by other investigators. This might be
due to the fact that 24 of our 31 evaluable patients presented
with highly advanced prostate cancer (>20 hot spots on
pre-treatment bone scan). This corresponds well with Laing
et al.'s (1991) suggestion that the response rate to 89Sr treat-
ment seems higher in patients with limited metastatic bone
involvement than in those with extensive skeletal metastases.
The most surprising result of our analysis was the fact that
PSA increased in about 3/4 of the patients during the first
2-3 months after 89Sr therapy and that APHOS decreased,
though to a lesser extent. The PSA increase is in contrast to
reports on the effect of secondary hormone treatment or
chemotherapy treatment, each of which reduces the PSA in
at least 20-50% of the patients (Scher et al., 1990; Fossa et
al., 1990; Denis et al., 1991). Such PSA decrease may even be
related to improved survival (Fossa et al., 1990). The
observed PSA increase within the first 2-3 months after the
89Sr injection may be explained by two alternatives, which
may be relevant either alone or in combination.
(1) The observed PSA increase mirrors a slow and pro-
longed release effect. 89Sr treatment represents a long-
acting irradiation with a half life time of 51 days of
radioactive substance. Though less likely, continuous
radiation-induced tumour cell death may during this
time hypothetically lead to a long-term release of PSA
to the patient's blood stream.
(2) Many patients with a high skeletal bone involvement
also have an extensive and most often undetected
tumour burden of soft tissue manifestations (retroperi-
toneal lymph node, liver metastases). Such metastases
would not be affected by 89Sr, as the drug is accum-
ulated in the bone and is effective only within 8 mm
from the radiation source. The continuous growth of
more distantly located and untreated soft tissue metas-
tases - as also demonstrated in three of our patients -
would thus explain the observed PSA increase, in spite
of tumour cell kill in bone metastases.
Our data on reduced serum APHOS levels and occasion-
ally decreased 9"Tc uptake suggest that 89Sr reduces the
activity of the osteoblasts, at least in some patients, as
observed by Robinson et al. (1989). However, it is still
uncertain how much this reduced activity of osteoblasts is
related to decreased volume of bone metastases and/or re-
presents an unspecific irradiation effect on the osteoblastic
cells. In any case, our observation of reduced APHOS early
after 89Sr injection, even in subjectively responding patients,
is in contrast to observations in patients responding to other
types of secondary systemic treatment. According to Mackin-
tosh et al. (1990) a transient increase of APHOS (1 months
after treatment start) is usually a sign of beneficial effect.
In conclusion intravenous 89Sr treatment represents a
worthwhile palliation treatment in patients with hormone-
resistant prostate cancer and metastatic bone pain. The treat-
ment is associated with increase of PSA and reduction of
APHOS within the first 3 months after the initial injection.
This study was financially supported by the Norwegian Cancer
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References
AARONSON, N.K., AHMEDZAI, S., BULLINGER, M., CRABEELS, D.,
ESTAPE, J., FILIBERTI, A. & 13 others (1991). The EORTC core
quality-of-life questionnaire: Interim results of an international
field study. In Effect of Cancer on Quality of Life. Osoba, D.
(ed.), pp. 185-202. CRC Press Inc: Boca Raton, Boston, Ann
Arbor, London.
BOLGER, J., QUILTY, P., KIRK, D., RUSSELL, J., REED, N., DEAR-
NALEY, D. & LEWINGTON, V. (1991). Trial of Metastron (Stron-
tium89) v conventional radiotherapy for osseous metastases from
prostate cancer (Abstract no. 685). ECCO 6 (Proceedings) S116.
DENIS, L., MAHLER, C., DE SMEDT, E., BRUYNSEELS, J., DE
COSTER, R. & JANSSEN, P. (1991). R 75251: A new cytotoxic
agent for relapsed metastatic prostate cancer. (Abstract no 702)
ECCO 6 (Proceedings), Si19.
DORREPAAL, K.L., AARONSON, N.K. & VAN DAM, F.S.A.M. (1989).
Pain experience and pain management among hospitalized cancer
patients. Cancer, 63, 93-598.
FOSSA, S.D., HOSBACH, G. & PAUS, E. (1990). Flutamide in hor-
mone-resistant prostatic cancer. J. Urol., 144, 1411-1414.
LAING, A.H., ACKERY, D.M., BAYLY, R.J., BUCHANAN, R.B., LEW-
INGTON, V.J. & MCEWAN, J.B. (1991). Strontium-89 chloride for
pain palliation in prostatic skeletal malignancy. Br. J. Radiol., 64,
816-822.
LEWINGTON, V.J., McEWAN, A.J., ACKERY, D.M., BAYLY, R.J.,
KEELING, D.H., MACLEOD, P.M., PORTER, A.T. & ZIVANOVIC,
M.A. (1991). A prospective, randomised double-blind crossover
study to examine the efficacy of strontium-89 in pain palliation in
patients with advanced prostate cancer metastatic to bone. Eur.
J. Cancer, 27, 954-958.
MACKINTOSH, J., SIMES, J., RAGHAVAN, D. & PEARSON, B. (1990).
Prostatic cancer with bone metastases: serum alkaline phospha-
tase (SAP) as a predictor of response and the significance of the
SAP 'flare'. Br. J. Urol., 66, 88-93.
MILLER, A.B., HOOGSTRATEN, B., STAQUET, M. & WINKLER, A.
(1981). Reporting results of cancer treatment. Cancer, 47, 207-
214.
ROBINSON, R.G., BLAKE, G.M., PRESTON, D.F., MCEWAN, A.J.,
SPICER, J.A., MARTIN, N.L., WEGST, A.V. & ACKERY, D.M.
(1989). Strontium-89: treatment results and kinetics in patients
with painful metastatic prostate and breast cancer in bone.
RadioGraphics, 9, 271-281.
SCHER, H.I., CURLEY, T., GELLER, N., ENGSTROM, C., DERSHAW,
D.D., LIN, S.Y., FITZPATRICK, K., NISSELBAUM, J., SCHWARTZ,
M., BEZIRDJIAN, L. & EISENBERGER, M. (1990). Trimetrexate in
prostatic cancer: preliminary observations on the use of prostate-
specific antigen and acid phosphatase as a marker in measurable
hormone-refractory disease. J. Clin. Oncol., 8, 1830-1838.
SOLOWAY, M.S., HARDEMEN, S.W., HICKEY, D., RAYMOND, J.,
TODD, B., SOLOWAY, S. & MOINUDDIN, M. (1988). Stratification
of patients with metastatic prostate cancer based on extent of
disease on initial bone scan. Cancer, 61, 195-202.
TANNOCK, I., GOSPODAROWICZ, M., MEAKIN, W., PANZARELLA,
T., STEWART, L. & RIDER, W. (1989). Treatment of metastatic
prostatic cancer with low-dose prednisone: evaluation ofpain and
quality of life as pragmatic indices of response. J. Clin. Oncol., 7,
590-597.
ZELEFSKY, M.J., SCHER, H.I., FORMAN, J.D., LINARES, L.A.,
CURLEY, T. & FUKS, Z. (1989). Palliative hemiskeletal irradiation
for widespread metastatic prostate cancer: a comparison of single
dose and fractionated regimens. Int. J. Radiat. Oncol. Biol. Phys.,
17, 1281-1285.